Scheduling of Carisoprodol to Schedule IV (Resolution No. 98-6-02)

May 23, 2002 3:19 pm Topics: Resolutions

Resolution No. 98-6-02
Title: Scheduling of Carisoprodol to Schedule IV

Whereas, the active metabolite of carisoprodol is meprobamate, a federal Schedule IV controlled substance; and

Whereas, the American Hospital Formulary Service monograph for carisoprodol states that, “daily ingestion of very large doses of carisoprodol (100 mg/kg for an unspecified number of days) has produced mild withdrawal symptoms such as abdominal cramps, insomnia, chilliness, headache, and nausea when the drug was abruptly discontinued…, and the drug should be used with caution in patients who have histories of drug abuse;” and

Whereas, several boards of pharmacy have designated carisoprodol a Schedule IV controlled substance; and

Whereas, with increased reports of abuse from state boards of pharmacy and law enforcement authorities, many states support strict controls on the prescribing and dispensing of carisoprodol; and

Whereas, the Drug Enforcement Administration (DEA) reports carisoprodol to be the most abused legend drug of noncontrolled status;

THEREFORE BE IT RESOLVED that NABP support the classification of carisoprodol as a federal Schedule IV controlled substance drug; and

BE IT FURTHER RESOLVED that NABP notify the Drug Enforcement Administration (DEA) and Food and Drug Administration (FDA) of its support for classifying carisoprodol as a federal Schedule IV controlled substance.

(Resolution passed at NABP’s 98th Annual Meeting, Phoenix, AZ)